United States Federal Circuit
Cancer Research Tech. Ltd. v. Barr Laboratories, Inc., 10-1204
In a patent infringement suit related to a genus of tetrazine derivative compounds and methods for treating cancer by administering those compounds, district court's judgment finding the '291 patent unenforceable for prosecution laches and inequitable conduct is reversed where: 1) the district court committed legal error in holding the '291 patent unenforceable for prosecution laches in the absence of any evidence of intervening rights; and 2) district court's decision holding the '291 patent unenforceable for inequitable conduct is reversed as the district court committed clear error in finding that plaintiff acted with deceptive intent.
Appellate Information
- Decided 11/09/2010
- Published 11/09/2010
Judges
Court
- United States Federal Circuit
Counsel
- For Appellant:
- Matthew D. Powers, George C. Lombardi